Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives Average Rating of "Hold" from Analysts

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) has been given a consensus rating of "Hold" by the seven research firms that are currently covering the stock, MarketBeat reports. Six research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $4.94.

A number of brokerages recently issued reports on IRWD. Wall Street Zen raised Ironwood Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Saturday, August 9th. Zacks Research lowered shares of Ironwood Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Friday, September 5th.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. State of Wyoming raised its holdings in Ironwood Pharmaceuticals by 249.9% during the second quarter. State of Wyoming now owns 205,644 shares of the biotechnology company's stock worth $147,000 after purchasing an additional 146,869 shares in the last quarter. Captrust Financial Advisors acquired a new position in Ironwood Pharmaceuticals during the 2nd quarter worth approximately $32,000. Tidal Investments LLC purchased a new position in shares of Ironwood Pharmaceuticals during the 2nd quarter worth approximately $222,000. Engineers Gate Manager LP raised its stake in shares of Ironwood Pharmaceuticals by 369.2% during the 2nd quarter. Engineers Gate Manager LP now owns 73,354 shares of the biotechnology company's stock worth $53,000 after buying an additional 57,720 shares in the last quarter. Finally, Bridgeway Capital Management LLC boosted its stake in shares of Ironwood Pharmaceuticals by 141.9% in the second quarter. Bridgeway Capital Management LLC now owns 75,000 shares of the biotechnology company's stock valued at $54,000 after buying an additional 44,000 shares in the last quarter.

Ironwood Pharmaceuticals Stock Up 5.6%

Ironwood Pharmaceuticals stock traded up $0.07 during midday trading on Monday, reaching $1.31. The company's stock had a trading volume of 816,432 shares, compared to its average volume of 1,247,972. The company has a market cap of $212.78 million, a P/E ratio of -26.19 and a beta of 0.33. The business has a 50-day simple moving average of $0.98 and a 200-day simple moving average of $0.97. Ironwood Pharmaceuticals has a fifty-two week low of $0.53 and a fifty-two week high of $5.13.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.16. Ironwood Pharmaceuticals had a negative return on equity of 2.46% and a negative net margin of 2.25%.The business had revenue of $85.24 million during the quarter, compared to analysts' expectations of $62.02 million. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that Ironwood Pharmaceuticals will post 0.1 earnings per share for the current year.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.